Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Takeda Pharmaceuticals International, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Our overall objective with this study is firstly to provide a comprehensive assessment of intestinal permeability, mucosal barrier function using existing biomarkers and secondly to explore novel biomarkers for measuring intestinal permeability in patients with constipation predominant Irritable Bowel Syndrome (IBS-C).
In order to determine the differences in permeability in IBS-C in comparison with healthy volunteers, the following will be determined: differences in in vivo small intestinal and colonic permeability, differences in small intestinal and colonic mucosal barrier function, differences in effects of fecal supernatants on barrier function of T84 monolayers, and differences in novel biomarkers for intestinal permeability
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy volunteers | Permeability measurement: Ingestion of saccharides {mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy |
| |
| IBS-C | Permeability measurement: Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Permeability measurement | Diagnostic Test | Saccharide excretion was compared between IBS-C and healthy volunteers |
|
| Measure | Description | Time Frame |
|---|---|---|
| Lactulose:C13 Mannitol Excretion Ratio 8-24hrs. | In vivo measurement of intestinal permeability using 13C mannitol & lactulose was used. High performance liquid chromatography-tandem mass spectrometry was used to measure concentrations calculated using the overall urine volume excreted in each interval. Concentrations of 13C adjusted for the % of 13C in 12C mannitol (4.98% of 12C mannitol excreted was subtracted from 13C mannitol values; determined by analyzing replicate samples of control urine). All lactulose or 13C mannitol concentrations 8-24hr post-ingestion were used to determine colonic permeability. Lactulose to 13C mannitol excretion ratios, as a measure of dose of saccharide administered, were calculated. | 8-24 hr post test-dose administration |
| Measure | Description | Time Frame |
|---|---|---|
| Lactose:C13 Mannitol Excretion Ratio 0-2hours | 0-2 hr post-test dose administration | |
| Baseline Transmucosal Resistance (TMR) of Duodenal Mucosa | Baseline | |
| Cumulative FITC-Dextran (4kDa) Concentration Across Duodenal Mucosa |
Not provided
Inclusion criteria:
Exclusion criteria:
History of Inflammatory Bowel Disease (IBD) , microscopic colitis or celiac disease
Use of tobacco products within the past 6 months
Use of NSAIDs or aspirin within the past week
Use of oral corticosteroids within the previous 6 weeks
Ingestion of artificial sweeteners such as Splenda (sucralose), Nutrasweet (aspartame), lactulose or mannitol 2 days before the study begins, e.g., foods to be avoided are sugarless gums or mints and diet soda
Ingestion of any prescription, over the counter, or herbal medications which can affect gastrointestinal transit 7 days before study begins
Any treatment specifically taken for IBS, including loperamide, cholestyramine, alosetron
Drugs with a known pharmacological activity at 5-HT4, 5-HT2b or 5-HT3 receptors (e.g, tegaserod, ondansetron, tropisetron, granisetron, dolasetron, mirtazapine);
All narcotics (e.g, codeine, morphine, and propoxyphene, either alone or in combination)
Anti-cholinergic agents (e.g, dicyclomine, hyoscyamine, propantheline).
Ultram
GI preparations
Antimuscarinics;
Peppermint oil;
Systemic antibiotics, rifaximin, metronidazole.
Bleeding disorders or medications that increase risk of bleeding from mucosal biopsies.
Score > 8 for anxiety or depression on Hospital anxiety and depression scale.
Pregnancy
Not provided
Not provided
IBS-Constipation patients and healthy volunteers
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Madhusudan Grover, MBBS | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Healthy Volunteers | Healthy subjects ages 18 - 65 Must not have had any abdominal surgeries, IBS, IBD, microscopic colitis or celiac disease. Must not have used tobacco products in the last 6 months. Must not have used corticosteroids in the last 6 weeks. Must not have taken any treatment specifically taken for IBS, including loperamide, cholestyramine, alosetron . Must not be taking any drugs with a known pharmacological activity at 5-HT4, 5-HT2b or 5-HT3 receptors. Must not have taken anti-cholinergic agents (e.g. dicyclomine, hyoscyamine, propantheline), Ultram. No GI preparations
|
| FG001 | IBS-C | Age (yr) 18 to 65 Must have IBS-C by Rome III criteria No abdominal surgery (except appendectomy and cholecystectomy) Exclusion criteria: Must have no History of IBD (Crohn's disease or ulcerative colitis), microscopic colitis or celiac disease. Use of tobacco products within the past 6 months (since nicotine may affect intestinal permeability) Use of NSAIDs or aspirin within the past week (since NSAIDs affect intestinal permeability) Use of oral corticosteroids within the previous 6 weeks No Ingestion of artificial sweeteners such as SplendaTM (sucralose), NutraSweet TM(aspartame), lactulose or mannitol 2 days before the study begins, e.g., foods to be avoided are sugarless gums or mints and diet soda. Ingestion of any prescription, over the counter, or herbal medications which can affect gastrointestinal transit 7 days before study begins ny treatment specifically taken for IBS, including loperamide, cholestyramine, alosetron No drugs with a known pharmacological activity at 5 |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Healthy Volunteers | Healthy volunteers between ages 18 - 65, who have not history of IBS. |
| BG001 | IBS-C | Volunteers who have been diagnosed with IBS - Constipation (IBS-C) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Lactulose:C13 Mannitol Excretion Ratio 8-24hrs. | In vivo measurement of intestinal permeability using 13C mannitol & lactulose was used. High performance liquid chromatography-tandem mass spectrometry was used to measure concentrations calculated using the overall urine volume excreted in each interval. Concentrations of 13C adjusted for the % of 13C in 12C mannitol (4.98% of 12C mannitol excreted was subtracted from 13C mannitol values; determined by analyzing replicate samples of control urine). All lactulose or 13C mannitol concentrations 8-24hr post-ingestion were used to determine colonic permeability. Lactulose to 13C mannitol excretion ratios, as a measure of dose of saccharide administered, were calculated. | Posted | Mean | Standard Error | Ratio | 8-24 hr post test-dose administration |
|
15 months-from the first participant screening to the last participants completion date
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Healthy Volunteer | Healthy volunteers between ages 18 - 65, who have no history of IBS. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Indigestion/Heartburn | Gastrointestinal disorders | Systematic Assessment | Indigestion/Heartburn |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Madhusudan Grover, MBBS | Mayo Clinic | 507-253-5384 | Grover.Madhusudan@mayo.edu |
Not provided
| ID | Term |
|---|---|
| D007410 | Intestinal Diseases |
| D043183 | Irritable Bowel Syndrome |
| D003248 | Constipation |
| ID | Term |
|---|---|
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D003109 | Colonic Diseases, Functional |
| D003108 | Colonic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D016145 | Endoscopy, Digestive System |
| ID | Term |
|---|---|
| D003938 | Diagnostic Techniques, Digestive System |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D004724 | Endoscopy |
Not provided
Not provided
Not provided
Not provided
Not provided
Colonic Biopsies Duodenal Biopsies Blood Urine Fecal
| Esophagogastroduodenoscopy | Procedure | Duodenal biopsies were collected from IBS-C and healthy volunteers |
|
| Flexible sigmoidoscopy | Procedure | Colonic biopsies were collected from IBS-C and healthy volunteers |
|
This is not a pharmacokinetic or pharmacodynamic measure. Hence only one time assessment is made 3 hours after FITC-Dextran (4kDa) administration. |
| 3 hours post FITC-Dextran (4kDa) administration |
| Rate of FITC-Dextran (4kDa) Flux Across Duodenal Mucosa | This is not a pharmacokinetic or pharmacodynamic measure. Hence only one time assessment is made 3 hours after FITC-Dextran (4kDa) administration. | Over 3 hours post FITC-Dextran (4kDa) administration |
| Baseline Transmucosal Resistance (TMR) of Colonic Mucosa | Baseline |
| Cumulative FITC-Dextran (4kDa) Concentration Across Colonic Mucosa | 3 hours post FITC-Dextran (4kDa) administration |
| Rate of FITC-Dextran (4kDa) Flux Across Colonic Mucosa | Over 3 hours post FITC-Dextran (4kDa) administration |
| Cumulative E.Coli Bio- Particle K12 Concentration Across Duodenal Mucosa | 3 hours post E.coli Bio- Particle administration |
| Rate of E.Coli Bio- Particle K12 Flux Across Duodenal Mucosa | Over 3 hours post E.coli Bio- Particle administration |
| Cumulative E.Coli Bio- Particle K12 Concentration Across Colonic Mucosa | 3 hours post E.coli Bio- Particle administration |
| Rate of E.Coli Bio- Particle K12 Flux Across Colonic Mucosa | Over 3 hours post E.coli Bio- Particle administration |
| Duodenal Impedance | Baseline |
| Mean Serum Endotoxin (Bacterial LPS) Levels | Fasting, one time measurement after 8 hours |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| OG001 | IBS - C | Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and (non-radioactive) 13C labeled mannitol, 100 mg and sucralose, 50 mg) in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy Esophagogastroduodenoscopy: Duodenal biopsies will be collected from IBS - C cases. Flexible sigmoidoscopy: Colonic biopsies will be collected from IBS - C cases. |
|
|
|
| Secondary | Lactose:C13 Mannitol Excretion Ratio 0-2hours | Posted | Mean | Standard Error | Ratio | 0-2 hr post-test dose administration |
|
|
|
| Secondary | Baseline Transmucosal Resistance (TMR) of Duodenal Mucosa | Two participants ( 1 in Healthy volunteers and 1 in IBS-C ) were not analysed for the Baseline transmucosal resistance (TMR) of duodenal mucosa due to various reasons such inadequate size of the biopsy specimen, participant did not show up for the procedure etc. | Posted | Mean | Standard Error | Ω*sq.cm | Baseline |
|
|
|
| Secondary | Cumulative FITC-Dextran (4kDa) Concentration Across Duodenal Mucosa | This is not a pharmacokinetic or pharmacodynamic measure. Hence only one time assessment is made 3 hours after FITC-Dextran (4kDa) administration. | Four participants (2 in Healthy volunteers and 2 in IBS-C) were not analysed for the Cumulative FITC-Dextran (4kDa) concentration across duodenal mucosa due to various reasons such inadequate size of the biopsy specimen, participant did not show up for the procedure, etc. | Posted | Mean | Standard Error | ng/mL | 3 hours post FITC-Dextran (4kDa) administration |
|
|
|
| Secondary | Rate of FITC-Dextran (4kDa) Flux Across Duodenal Mucosa | This is not a pharmacokinetic or pharmacodynamic measure. Hence only one time assessment is made 3 hours after FITC-Dextran (4kDa) administration. | Four participants ( 2 in Healthy volunteers and 2 in IBS-C ) were not analysed for the Rate of FITC-Dextran (4kDa) flux across duodenal mucosa due to various reasons such inadequate size of the biopsy specimen, participant did not show up for the procedure etc. | Posted | Mean | Standard Error | ng/hr/sq.cm | Over 3 hours post FITC-Dextran (4kDa) administration |
|
|
|
| Secondary | Baseline Transmucosal Resistance (TMR) of Colonic Mucosa | One participant in IBS-C was not analysed for the Baseline Transmucosal Resistance (TMR) of Colonic Mucosa due to various reasons such inadequate size of the biopsy specimen. | Posted | Mean | Standard Error | Ω*sq.cm | Baseline |
|
|
|
| Secondary | Cumulative FITC-Dextran (4kDa) Concentration Across Colonic Mucosa | 7 participants (2 in Healthy volunteers and 5 in IBS-C) were not analysed for the Cumulative FITC-Dextran (4kDa) Concentration Across Colonic Mucosa due to various reasons such inadequate size of the biopsy specimen, participant did not show up for the procedure, etc. | Posted | Mean | Standard Error | ng/mL | 3 hours post FITC-Dextran (4kDa) administration |
|
|
|
| Secondary | Rate of FITC-Dextran (4kDa) Flux Across Colonic Mucosa | 7 participants (2 in Healthy volunteers and 5 in IBS-C) were not analysed for the Rate of FITC-Dextran (4kDa) Flux Across Colonic Mucosa due to various reasons such inadequate size of the biopsy specimen, participant did not show up for the procedure, etc. | Posted | Mean | Standard Error | ng/hr/sq.cm | Over 3 hours post FITC-Dextran (4kDa) administration |
|
|
|
| Secondary | Cumulative E.Coli Bio- Particle K12 Concentration Across Duodenal Mucosa | 11 participants (4 in Healthy volunteers and 7 in IBS-C) were not analysed for Cumulative E.Coli Bio- Particle K12 Concentration Across Duodenal Mucosa due to various reasons such inadequate size of the biopsy specimen, participant did not show up for the procedure, etc. | Posted | Mean | Standard Error | CFU/ml | 3 hours post E.coli Bio- Particle administration |
|
|
|
| Secondary | Rate of E.Coli Bio- Particle K12 Flux Across Duodenal Mucosa | 11 participants (4 in Healthy volunteers and 7 in IBS-C) were not analysed for Rate of E.Coli Bio- Particle K12 Flux Across Duodenal Mucosa due to various reasons such inadequate size of the biopsy specimen, participant did not show up for the procedure, etc. | Posted | Mean | Standard Error | CFU/h/sq.cm | Over 3 hours post E.coli Bio- Particle administration |
|
|
|
| Secondary | Cumulative E.Coli Bio- Particle K12 Concentration Across Colonic Mucosa | 7 participants (2 in Healthy volunteers and 5 in IBS-C) were not analysed for Cumulative E.coli Bio- Particle K12 Concentration Across Colonic Mucosa due to various reasons such inadequate size of the biopsy specimen, participant did not show up for the procedure, etc. | Posted | Mean | Standard Error | CFU/ml | 3 hours post E.coli Bio- Particle administration |
|
|
|
| Secondary | Rate of E.Coli Bio- Particle K12 Flux Across Colonic Mucosa | 7 participants (2 in Healthy volunteers and 5 in IBS-C) were not analysed for Rate of E.Coli Bio- Particle K12 Flux Across Colonic Mucosa due to various reasons such inadequate size of the biopsy specimen, participant did not show up for the procedure, etc. | Posted | Mean | Standard Error | CFU/h/sq.cm | Over 3 hours post E.coli Bio- Particle administration |
|
|
|
| Secondary | Duodenal Impedance | 12 participants (2 in Healthy volunteers and 10 in IBS-C) were not analysed for Duodenal impedance due to various reasons such inadequate size of the biopsy specimen, participant did not show up for the procedure, etc. | Posted | Mean | Standard Error | Ω | Baseline |
|
|
|
| Secondary | Mean Serum Endotoxin (Bacterial LPS) Levels | 2 participants (1 in healthy volunteers and 1 in IBS-C) were not analysed for Mean Serum Endotoxin (Bacterial LPS) Levels due to various reasons such as non-availability of the blood sample, technical errors, etc. | Posted | Mean | Standard Error | EU/mL | Fasting, one time measurement after 8 hours |
|
|
|
| 0 |
| 18 |
| 0 |
| 18 |
| 0 |
| 18 |
| EG001 | IBS-C | ROME III IBS-C patients | 0 | 19 | 0 | 19 | 1 | 19 |
|
Not provided
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003949 | Diagnostic Techniques, Surgical |
| D013505 | Digestive System Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
| D019060 | Minimally Invasive Surgical Procedures |